Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Treatment of metabolic acidosis,Correction of electrolyte disturbances
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous (IV) infusion: Initial dose 300-500 m L of 1/6 M (M/6) sodium lactate solution (167 m Eq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
The terminal elimination half-life of lactate is approximately 5–10 minutes due to rapid hepatic metabolism; this short half-life allows quick correction of metabolic acidosis when administered intravenously.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Metabolized in the liver via lactate dehydrogenase and the Cori cycle to bicarbonate and glucose.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Sodium lactate is metabolized to bicarbonate in the liver via the Cori cycle; less than 5% is excreted unchanged in urine under normal conditions. Biliary/fecal elimination is negligible.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Minimal protein binding (<5%) as lactate is a small, water-soluble molecule; not significantly bound to plasma proteins.
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Volume of distribution approximates total body water (0.5–0.6 L/kg) because lactate distributes freely into the extracellular and intracellular spaces; this reflects its rapid equilibration.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100% (administered directly into the bloodstream). Oral: Not clinically used; oral administration is not bioavailable as lactate is metabolized in the gut and liver first-pass.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of fluid overload and hypernatremia; for GFR 30-59 m L/min, use with caution and reduce infusion rate by 50%.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
Child-Pugh Class A: No adjustment; Class B: Use with caution, reduce dose by 25%; Class C: Avoid use due to impaired lactate metabolism.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Neonates and infants: 4.5 m L/kg of M/6 sodium lactate IV over 1 hour; children: 20-30 m L/kg of M/6 sodium lactate IV at a rate not exceeding 10 m L/kg/hour, titrated to monitoring of acid-base status.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Elderly patients: Start at low end of dosing range, monitor for fluid overload, hypernatremia, and metabolic alkalosis; infusion rate not to exceed 100 m L/hour due to reduced cardiac and renal reserve.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None
None
Use with caution in patients with lactic acidosis if etiology is not correctable,Monitor serum electrolytes, acid-base status, and fluid balance,Risk of fluid overload in patients with heart failure or renal impairment
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Severe metabolic alkalosis,Hypernatremia (if sodium-containing),Lactic acidosis not due to correctable causes
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No known dietary restrictions or food interactions. However, monitor nutritional intake in patients receiving long-term therapy, as electrolyte imbalances may require dietary adjustments.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal harm at doses within clinical range. However, no well-controlled human studies exist. The risk is considered low but cannot be excluded. Use in pregnancy only if clearly needed.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Sodium lactate is a normal constituent of plasma and breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio is not established but expected to be near 1. It is considered compatible with breastfeeding.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No specific dose adjustments required for pregnancy. However, monitor for fluid overload and electrolyte disturbances, especially in preeclampsia or renal impairment.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
Sodium lactate in plastic container is used as a source of bicarbonate precursor for metabolic acidosis. It is contraindicated in lactic acidosis because it requires hepatic metabolism to bicarbonate. Monitor serum lactate and p H closely during infusion. The plastic container may leach DEHP; use with caution in neonates and pregnant women.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This medication is given intravenously to correct acid buildup in the blood.,Tell your healthcare provider if you have liver disease, as it may affect how this drug works.,Inform your doctor if you are pregnant or breastfeeding.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Do not suddenly stop treatment without consulting your doctor.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE IN PLASTIC CONTAINER is: Intravenous (IV) infusion: Initial dose 300-500 m L of 1/6 M (M/6) sodium lactate solution (167 m Eq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal ha. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.